Deswell Announces First Half 2023 Results
- Company Announces First Half Cash Dividend of $0.10 Per Share - MACAO--(BUSINESS WIRE)--Deswell Industries,…
4 years ago
Pacific Defense Awarded Defense Innovation Unit Contract to Deliver Assured PNT 3U Cards for Army and Broader DoD adoption
EL SEGUNDO, Calif.--(BUSINESS WIRE)--#USARMY--Pacific Defense, a leading open systems integrator delivering Modular Open Systems Approach…
4 years ago
Australasian Inter-Service Incident Management System (AIIMS) Tecnologies & Tools – Main Players Analysis – 2022 Report – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Australasian Inter-Service Incident Management System (AIIMS) Tecnologies & Tools - Main Players Analysis…
4 years ago
Asahi Kasei Starts Selling BR and S-SBR Made Using the Mass-balance Method
— Toward achievement of sustainability — NEW YORK & DÜSSELDORF, Germany & TOKYO--(BUSINESS WIRE)--#asahikasei--Asahi Kasei,…
4 years ago
ASTER_Wise Solution to Serve the Smart Community in Indonesia
AR/VR interactive caring and epidemic prevention are advanced smart technologies JAKARTA TIMUR, Indonesia--(BUSINESS WIRE)--ASTER_Wise Smart…
4 years ago
City of Tampere: Finland in Co-operation With Japan in Human-Centred Smart Urban Development
TAMPERE, Finland--(BUSINESS WIRE)--#AuroraAI--Tampere, one of Finland's largest cities, is the first in Europe to introduce…
4 years ago
Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China
Collaboration leverages Tenacia’s CNS, R&D, and local market expertise to support expansion of ganaxolone’s development…
4 years ago
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
BRUKINSA is the only Bruton’s Tyrosine Kinase (BTK) inhibitor to achieve superiority over IMBRUVICA® (ibrutinib)…
4 years ago
Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction
AZR-MD-001 0.5% meets co-primary efficacy endpoints, making it the first investigational drug to show significant…
4 years ago
Genius Group to Announce Third Quarter 2022 Financial Results
SINGAPORE--(BUSINESS WIRE)--$GNS #GNS--Genius Group Limited (“Genius Group” or the “Company”) (NYSE American: GNS), will announce…
4 years ago